EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes

Margherita Ratti, Chiara Citterio iD, Elena Orlandi iD, Stefano Vecchia iD, Elisa Anselmi, Ilaria Toscani iD, Martina Rotolo, Massimiliano Salati, Michele Ghidini iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157285 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Margherita Ratti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology and Hematology Department, Piacenza General Hospital, Via Taverna 49, 29121 Piacenza, PC, Italy. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) remains a major cause of cancer-related mortality worldwide, with human epidermal growth factor receptor 2 (HER2)-positive disease representing a clinically relevant subset. Trastuzumab combined with chemotherapy is the standard first-line treatment in advanced settings, following the landmark ToGA trial. However, resistance to trastuzumab has emerged as a significant limitation, prompting the need for more effective second-line therapies. Trastuzumab deruxtecan, a novel antibody–drug conjugate (ADC) composed of trastuzumab linked to a cytotoxic payload, has demonstrated promising efficacy in trastuzumab-refractory, HER2-positive GC, including cases with heterogeneous HER2 expression. Other HER2-targeted ADCs are also under investigation as potential alternatives. In addition, strategies to overcome resistance include HER2-specific immune-based therapies, such as peptide vaccines and chimeric antigen receptor T cell therapies, as well as antibodies targeting distinct HER2 domains or downstream signaling pathways like PI3K/AKT. These emerging approaches aim to improve efficacy in both HER2-high and HER2-low GC. As HER2-targeted treatments evolve, addressing resistance mechanisms and optimizing therapy for broader patient populations is critical. This review discusses current and emerging HER2-directed strategies in GC, focusing on trastuzumab deruxtecan and beyond, and outlines future directions to improve outcomes for patients with HER2-positive GC across all clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansTrastuzumabDrug Resistance, NeoplasmImmunoconjugatesMolecular Targeted TherapyAntineoplastic Agents, ImmunologicalSignal Transduction

Stichwörter der Autor:innen

HER2HER2-directed strategiesgastric cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabImmunoconjugatesAntineoplastic Agents, ImmunologicalERBB2 protein, human

Autor:innen und Institutionen

  • Oncology and Hematology Department, Piacenza General Hospital, Via Taverna 49, 29121 Piacenza, PC, Italy.
  • Pharmacy Unit, Piacenza General Hospital, Via Taverna 49, 29121 Piacenza, PC, Italy.
  • School of Medical Oncology, University Hospital of Modena and Reggio Emilia, Largo del Pozzo 71, 41124 Modena, MO, Italy.
  • Division of Medical Oncology, University Hospital of Modena, 41124 Modena, MO, Italy.
  • Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, MI, Italy.

ORCID-Profile: Chiara Citterio, Elena Orlandi, Stefano Vecchia, Ilaria Toscani, Michele Ghidini

Zitieren

APA

Ratti, M., Citterio, C., Orlandi, E., Vecchia, S., Anselmi, E., Toscani, I., Rotolo, M., Salati, M., & Ghidini, M. (2025). Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157285

Vancouver

Ratti M, Citterio C, Orlandi E, Vecchia S, Anselmi E, Toscani I, et al. Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157285

BibTeX
@article{Ratti2025,
  author = {Ratti, Margherita and Citterio, Chiara and Orlandi, Elena and Vecchia, Stefano and Anselmi, Elisa and Toscani, Ilaria and Rotolo, Martina and Salati, Massimiliano and Ghidini, Michele},
  title = {Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157285}
}
Kostenlos starten →